Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 14;19(1):522.
doi: 10.1186/s12879-019-4146-5.

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017)

Shamez N Ladhani  1   2 , Helen Campbell  3 , Jay Lucidarme  4 , Steve Gray  4 , Sydel Parikh  3 , Laura Willerton  4 , Stephen A Clark  4 , Aiswarya Lekshmi  4 , Andrew Walker  4 , Sima Patel  4 , Xilian Bai  4 , Mary Ramsay  3 , Ray Borrow  4
Affiliations

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017)

Shamez N Ladhani et al. BMC Infect Dis. .

Abstract

Background: To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade.

Methods: Public Health England conducts enhanced surveillance of IMD in England. We retrospectively identified patients with complement deficiency who developed IMD in England during 2008-2017 and retrieved information on their clinical presentation, vaccination status, medication history, recurrence of infection and outcomes, as well as characteristics of the infecting meningococcal strain.

Results: A total of 16 patients with 20 IMD episodes were identified, including four with two episodes. Six patients had inherited complement deficiencies, two had immune-mediated conditions associated with complement deficiency (glomerulonephritis and vasculitis), and eight others were on Eculizumab therapy, five for paroxysmal nocturnal haemoglobinuria and three for atypical haemolytic uraemic syndrome. Cultures were available for 7 of 11 episodes among those with inherited complement deficiencies/immune-mediated conditions and the predominant capsular group was Y (7/11), followed by B (3/11) and non-groupable (1/11) strains. Among patients receiving Eculizumab therapy, 3 of the 9 episodes were due to group B (3/9), three others were NG but genotypically group B, and one case each of groups E, W and Y.

Conclusions: In England, complement deficiency is rare among IMD cases and includes inherited disorders of the late complement pathway, immune-mediated disorders associated with low complement levels and patients on Eculizumab therapy. IMD due to capsular group Y predominates in patient with inherited complement deficiency, whilst those on Eculizumab therapy develop IMD due to more diverse capsular groups including non-encapsulated strains.

Keywords: Complement deficiency; Eculizumab; Invasive meningococcal disease; Risk factors.

PubMed Disclaimer

Conflict of interest statement

AL, AW, JL, LW, RB, SAC, SG, SL, SP and XB perform contract research on behalf of Public Health England for GSK, Pfizer and Sanofi Pasteur. All other authors: no conflict.

References

    1. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861. doi: 10.1016/S1473-3099(10)70251-6. - DOI - PubMed
    1. Caugant DA, Maiden MC. Meningococcal carriage and disease--population biology and evolution. Vaccine. 2009;27(Suppl 2):B64–B70. doi: 10.1016/j.vaccine.2009.04.061. - DOI - PMC - PubMed
    1. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet. 2010;42:772–776. doi: 10.1038/ng.640. - DOI - PubMed
    1. Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5:98–126. doi: 10.4161/viru.26515. - DOI - PMC - PubMed
    1. Rosain J, Hong E, Fieschi C, Martins PV, El Sissy C, Deghmane AE, et al. Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies. J Infect Dis. 2017;215:1331–1338. doi: 10.1093/infdis/jix143. - DOI - PubMed

MeSH terms

Substances